SEC Tracker
Get the app
TVRD · XBRL financial data

Tvardi Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (TVRD's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024†Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers4,8663,004*2,1359912,5561,455*2,569—————
Research and development25,45128,415*21,9649,3081,362171*3195,8063,6035,491*4,9114,002
General and administrative6,7556,588*6,8166,4086,4756,831*4,6363,0632,3352,096*2,1402,627
Total operating expenses33,76435,611*31,80118,2978,5446,878*4,9558,8695,9387,587*7,0516,629
Operating income (loss)(28,898)(32,607)*(29,666)(17,306)(5,988)(5,423)*(2,386)(8,869)(5,938)(7,587)*(7,051)(6,629)
Interest income———200200100*—100300100*—200
Interest expense——————55893*————
Other income (expense)866874*952689766421*34712,6590*0*——
Income tax expense (benefit)00*000(398)*0——year only——
Net income (loss)(28,032)(32,337)*(30,696)(20,016)(12,476)(7,679)*(4,906)4,167(5,527)(7,275)*(6,804)(6,457)
Earnings per share, basic‡ USD per share(6.27)(7.11)*(6.75)(4.46)(2.77)(1.66)*(3.22)0.51(0.59)—(0.73)(0.69)
Earnings per share, diluted‡ USD per share(6.27)(7.11)*(6.75)(4.46)(2.77)(1.66)*(3.22)(1.00)(0.59)—(0.73)(0.69)
Weighted average shares, basic‡ thousands of shares4,5024,522*4,5314,5424,5524,625*1,5248,2479,377—9,3819,381
Weighted average shares, diluted‡ thousands of shares4,5024,522*4,5314,5424,5524,625*1,5248,4559,377—9,3819,381
  • ‡ Per-share figures and share counts are adjusted for the 1-for-12.048192771084336 stock split (December 2024); filings made before it reported them unadjusted.
  • † Share count changed about 2x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (TVRD's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024†Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents62,87551,77546,99649,23937,06137,90334,21720,64821,41820,73419,85115,765
Short-term investments———————20,34615,04210,0775,130—
Accounts receivable3,3512,7651,7183594354071,229—————
Inventory3,2662,8212,7411,644625900900—————
Prepaid and other current assets—————72—2,1361,9837273451,304
Total current assets100,603116,15881,22563,85947,91243,827—43,13038,44331,53825,32617,069
Property and equipment, net1,3803,3223,5483,4903,41784—6860524436
Right-of-use asset7,1084,8643,8263,646—2160181163144124104
Total assets115,338125,84490,09972,49551,32943,82738,94743,75039,02132,07325,81717,517
Accounts payable7,97811,5834,9786,7552,5411,43442,4254,0783,2194,6204,638
Accrued liabilities—————8,078—8,1446,8497,7076,5184,352
Total current liabilities22,88125,59215,09513,90110,0393,9721,19910,67811,04011,04211,2589,113
Lease liability, non-current6,8156,0886,8257,320—201—145115855422
Total liabilities—68,75960,29660,89750,62248,42047,02010,82311,15511,12711,3129,135
Accumulated deficit(652,408)(684,745)(715,441)(735,457)(747,933)(755,612)(760,518)(97,648)(103,175)(110,450)(117,254)(123,711)
Total stockholders' equity85,64257,08529,80311,598707(4,593)(8,073)32,92727,86620,94614,5058,382
Total liabilities and equity115,338125,84490,09972,49551,32943,82738,94743,75039,02132,07325,81717,517
Common shares outstanding (cover page)‡ thousands of shares4,5224,5364,5384,5524,5534,5749,3619,3779,3819,3819,38113,339
  • ‡ Per-share figures and share counts are adjusted for the 1-for-12.048192771084336 stock split (December 2024); filings made before it reported them unadjusted.
  • † Share count changed about 2x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (TVRD's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024†Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(28,032)(32,337)*(30,696)(20,016)(12,476)(7,679)*(4,906)4,167(5,527)(7,275)*(6,804)(6,457)
Stock-based compensation3,334*3,601*3,3451,741*1,489*2,354*1,426(719)*339*353*370335*
Depreciation and amortization59*82*4277*73*0*047*24*24*2423*
Net cash from operating activities(19,645)*(17,370)*(30,453)(12,437)*(13,984)*(4,043)*(4,692)(8,865)*(4,257)*(5,685)*(5,859)(9,228)*
Purchases of property and equipment—2,052*836210*0*0*——————
Net cash from investing activities23,155*(30,205)*25,95115,290*2,500*5,000*(10,883)(9,550)*5,349*5,000*4,9765,142*
Proceeds from issuing common stock—0*——————————
Net cash from financing activities1,116*36,475*(685)(610)*(694)*(1,615)*1,00622,018*(322)*1*——
Net change in cash————(6,669)*22,176*(20,175)9,209*770*(684)*(883)(4,086)*
  • † Share count changed about 2x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Tvardi Therapeutics15,765not reported(9,228)*13.3M1.7 quarters 10-QJun 30, 2026
Silence Therapeutics72,05401,518*141.7M— 10-QJun 30, 2026
Cardiff Oncology9,197104(11,765)*77.8M2.9 quarters 10-QJun 30, 2026
Rezolute10,615not reported(13,146)*96.7M8.2 quarters 10-KJun 30, 2026
Natures Sunshine Products82,503116,985835*17.6M— 10-QJun 30, 2026
Rocket Pharmaceuticals224,5070(39,613)*109.8M7.2 quarters 10-QJun 30, 2026
Perspective Therapeutics48,488not reported(20,650)*114.2M11.5 quarters 10-QJun 30, 2026
Esperion Therapeutics156,15880,104(27,722)257.4M5.6 quarters 10-QMar 31, 2026
Palvella Therapeutics187,803not reported(12,845)*14.4M19.5 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.